The Biomarker Development Center (BDC) is a public-private partnership supported by a number of stakeholders. The stakeholders represent global industrial players in the diagnostic and pharmaceutical area, patient organizations and representative of the public sector involved in research policy making. Some members of these organizations and industries have agreed to take seat in the Scientific Advisory Board of the BDC. Current members are the following:
- Dr. Claudio Carini, Pfizer, Global Clinical Immunology & Biomarkers Lead, Cambridge, MA, USA
- Dr. Kees Smaling, Siemens Healthcare, CEO Healthcare Siemens Nederland N.V., Den Haag, The Netherlands
- Dr. Khusru Asadullah, Professor at the Charité, Berlin, Germany (on leave from Bayer Pharma AG)
- Dr. Wim Timens, eQTL Lung consortium, Head of Pathology, University Medical Center Groningen, The Netherlands
Together this group of experts will cooperate with the principal investigators and the industry partners to define the strategy of the BDC and notably to evaluate progress critically.